Intercure Ltd

InterCure Ltd. engages in the business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies and Investments in Medical Cannabis Companies segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

InterCure reports record 2022 revenues, poised for global expansion

InterCure had a successful year in 2022, achieving record revenues and positioning itself for global expansion. The company's focus on the Israeli market, expansion of cultivation facilities, and addition of new product strains have been key drivers of growth. Despite challenges in patient procurement and regulatory complexities, InterCure is well-prepared to leverage opportunities in international markets.

InterCure reports record revenue and positive cash flow for 2022

InterCure's Q4 2022 earnings call highlighted a successful 2022, with record revenue and positive cash flow. The company's focus on leading the Israeli market, scaling up operations, and navigating market dynamics and regulatory differences positions it for continued growth. Despite industry challenges, InterCure is well-prepared to capitalize on opportunities presented by pricing trends and prescription reforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies in the Biomed Sector and Investments in the Medical Cannabis Sector segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

InterCure Ltd. (NASDAQ:INCR ) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET Company Participants Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Vivien Azer - Cowen and Company Matt Bottomley - Canaccord Genuity Pablo Zuanic - Zuanic & Associates Operator Thank you for standing by, and welcome to InterCure's Fourth Quarter 2022 Earnings Call.

InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript

NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022.

InterCure Reschedules 2022 Full Year Results Conference Call

Record fiscal year 202 2 revenue of $ 150 million

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most profitable cannabis company outside of north America, announced today that it has filed a lawsuit against Cann Pharmaceuticals Ltd. (dba “Better”), a company with which it had previously sought to merge, to recover funds loaned and invested in the course of their dealings in connection with the merger agreement.

InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, further to the merger agreement with Cann Pharmaceutical Ltd. (“Better”) dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better (the “Agreement”), and further to the Company's press release dated November 23, 2022 regarding the fundamental disagreements between the parties, that the closing conditions contained in the Agreement were not met and the Agreement was terminated.

InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

InterCure earned CAD$39 million in Q3 2022, up 61.2% from the previous year. Moreover, at the end of Q4 2022, the total number of licensed patients using cannabis for medical purposes in Israel was 123,212, up 13,860 from the previous year.

InterCure: Why The Company Is Grossly Undervalued By Wall Street

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Trulieve Cannabis Corp.

Negative conditions are crashing down all around investors. Make sure companies in your portfolio will survive.

Cannabis Is A Long-Term Play (Podcast Transcript)

Aurora Cannabis

AFC Gamma

Beyond Meat

Cara Therapeutics

Canopy Growth

Amplify Seymour Cannabis ETF

Cronos Group

Direxion Daily CSI China Internet Index Bull 2X Shares

Flora Growth Corp

GrowGeneration Corp

GW Pharmaceuticals

High Tide

Hydrofarm Holdings Group

Innovative Industrial Properties

Amplify Alternative Harvest ETF

Cannabis REITs have been slammed this year amid concern over defaults from their cannabis cultivator tenants, which have been smoked by plunging wholesale cannabis prices and setbacks on federal legalization. The exclusion of the SAFE Banking Act from the omnibus federal spending package dimmed the once-high hopes that major federal marijuana legislation would be passed during the Biden Presidency.

Cannabis REITs: Smoked Out

Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske” Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske”

InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"

Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate

InterCure to Participate in Cowen 5th Annual Cannabis Conference

NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce the withdrawal of a class action lawsuit against it (the “Regenera Lawsuit”). The Regenera Lawsuit was described in the Company's press release dated May 26, 2020 and in the Company's most recent Annual Report and Annual Information Form and it was primarily concerning a motion to certify, as a class action, a claim filed against the Company, its directors and its executive officers, alleging that the Company violated its obligation to publicly disclose certain events and developments which impacted the valuation of Regenera Pharma Ltd. (in which the Company held a 11.76% position during the time relevant to the claim). On December 2, 2022, the Tel Aviv District Court approved a consent motion to withdraw the Regenera Lawsuit, without any payment to the plaintiff from the Company.

InterCure Announces the Withdrawal of a Class Action Lawsuit against it

NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an update that further to the announcement from February 16, 2022, regarding the signed agreement with Cann Pharmaceutical Ltd. (“Better”) to acquire 100% of Better's shares (the “Transaction”), which as set out in the Company's reports is subject to certain closing conditions, as of this date, there are some fundamental disagreements between the parties (including open matters which were not concluded at the time of the signing the agreement), in addition to a disconnect between the parties, which pose doubts as to whether the Transaction will in fact be completed.

Update regarding Better Transaction

Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

OrganiGram Holdings Inc.

TORONTO & HERZILA, Israel--( BUSINESS WIRE )--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U) (TASE:INCR) (dba Canndoc) Israel's largest and most established pharmaceutical cannabis producer, today jointly announced that they have entered into a new multi-year agreement (the “New Strategic Agreement”) for Organigram to continue supply of dried flower to InterCure.

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, by InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), please note that multiple numbers were incorrect and have been updated. The corrected release follows:

CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Eleventh consecutive quarter of sequential profitable revenue growth

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Estimated revenue reaches CAD$39 million 1  (a record of over NIS 100 million) :

InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY

Legal cannabis around the world is just beginning but will surpass that of North America. Europe is one of the largest growth markets for companies in global cannabis.

Buy InterCure To Ride The Coming Wave Of Global Cannabis Growth

InterCure is the leading cannabis operator in Israel. Israel is currently a medical market, with recreational legalization expected to occur over the coming years.

InterCure: Highlighting A Profitable Israeli Cannabis Operator

HERZLIYA, Israel, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intercure Ltd. (the “Company”) announces today the results of the Annual and Special General Meeting of shareholders of the Company, held on Thursday, September 15, 2022, in Bnei Brak, Israel (the “Meeting”). At the Meeting, all of the proposals set forth in the Company's management information circular dated August 10, 2022 (the “Circular”) were approved by the required majority of the shareholders.

Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders

The global cannabis market will eventually be far bigger than North America. InterCure is a leading company in global pharmaceutical cannabis.

InterCure: A Leader In Global Cannabis

InterCure Ltd (NASDAQ:INCR ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Adam Haliva - Communications Officer Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Victor Ma - Cowen and Company Pablo Zuanic - Cantor Fitzgerald Yewon Kang - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the InterCure Second Quarter 2022 Earnings Call and Webcast.

InterCure Ltd (INCR) CEO Alexander Rabinovitch on Q2 2022 Results - Earnings Call Transcript

Record revenue of over $3 7 million i in the second quarter of 2022

InterCure Reports Record Breaking Second Quarter Financial Results

Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET

InterCure to Release its Q2 2022 Results and Hold a Conference Call

Clever Leaves Holdings Inc

Greenlane Holdings

Incannex Healthcare Inc

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

News for Intercure Ltd Stock (INCR)